Serious safety events in rituximab‐treated multiple sclerosis and related disorders

INTRODUCTION: Studies investigating rates and risk factors for serious safety events (SSEs) during rituximab treatment of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and related disorders are limited. METHODS: Rituximab‐treated patients with MS, NMOSD, or related disord...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Brandi L., Wallach, Asya I., Corboy, John R., Dubovskaya, Karolina, Alvarez, Enrique, Kister, Ilya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480911/
https://www.ncbi.nlm.nih.gov/pubmed/32767531
http://dx.doi.org/10.1002/acn3.51136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7480911/
https://www.ncbi.nlm.nih.gov/pubmed/32767531
http://dx.doi.org/10.1002/acn3.51136

Ejemplares similares